These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Natural history of multiple sclerosis: early prognostic factors. Mowry EM Neurol Clin; 2011 May; 29(2):279-92. PubMed ID: 21439441 [TBL] [Abstract][Full Text] [Related]
4. [Functional magnetic resonance imaging in multiple sclerosis]. Korsholm K; Mathiesen HK; Lund TE Ugeskr Laeger; 2007 Jun; 169(26):2518-20. PubMed ID: 17725897 [TBL] [Abstract][Full Text] [Related]
5. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Thompson AJ; Kermode AG; MacManus DG; Kendall BE; Kingsley DP; Moseley IF; McDonald WI BMJ; 1990 Mar; 300(6725):631-4. PubMed ID: 2138923 [TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis and magnetic resonance imaging: advancement in linking the pictures with the progression. Racke MK; Hawker K; Frohman EM Arch Neurol; 2001 Jan; 58(1):35-6. PubMed ID: 11176933 [No Abstract] [Full Text] [Related]
7. Proton MR spectroscopy in multiple sclerosis. Arnold DL; De Stefano N; Narayanan S; Matthews PM Neuroimaging Clin N Am; 2000 Nov; 10(4):789-98 ,ix-x. PubMed ID: 11359725 [TBL] [Abstract][Full Text] [Related]
9. 'Time is brain' also in multiple sclerosis. Freedman MS Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740 [No Abstract] [Full Text] [Related]
10. Evoked potential abnormality scores are a useful measure of disease burden in relapsing-remitting multiple sclerosis. O'Connor P; Marchetti P; Lee L; Perera M Ann Neurol; 1998 Sep; 44(3):404-7. PubMed ID: 9749611 [TBL] [Abstract][Full Text] [Related]
11. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--no. Filippi M; Rocca MA Mult Scler; 2012 May; 18(5):557-8. PubMed ID: 22547411 [No Abstract] [Full Text] [Related]
13. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. Paling D; Solanky BS; Riemer F; Tozer DJ; Wheeler-Kingshott CA; Kapoor R; Golay X; Miller DH Brain; 2013 Jul; 136(Pt 7):2305-17. PubMed ID: 23801742 [TBL] [Abstract][Full Text] [Related]
14. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--yes. Geurts JJ Mult Scler; 2012 May; 18(5):559-60. PubMed ID: 22547412 [No Abstract] [Full Text] [Related]
15. Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. Giorgio A; Portaccio E; Stromillo ML; Marino S; Zipoli V; Battaglini M; Blandino A; Bartolozzi ML; Siracusa G; Amato MP; De Stefano N Mult Scler; 2010 Nov; 16(11):1326-34. PubMed ID: 20670979 [TBL] [Abstract][Full Text] [Related]
16. MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge. Jacobsen CO; Farbu E Acta Neurol Scand Suppl; 2014; (198):32-6. PubMed ID: 24588504 [TBL] [Abstract][Full Text] [Related]
17. MRI findings in benign multiple sclerosis are variable. Pittock SJ; Noseworthy JH; Rodriguez M J Neurol; 2007 Apr; 254(4):539-41. PubMed ID: 16944348 [No Abstract] [Full Text] [Related]
18. Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials. Simon JH West J Med; 1996 Jun; 164(6):502-9. PubMed ID: 8764625 [TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: the importance of early recognition and treatment. Fox RJ; Cohen JA Cleve Clin J Med; 2001 Feb; 68(2):157-71. PubMed ID: 11220457 [TBL] [Abstract][Full Text] [Related]
20. The natural history of multiple sclerosis. Deshpande R; Kremenchutzky M; Rice GP Adv Neurol; 2006; 98():1-15. PubMed ID: 16400823 [No Abstract] [Full Text] [Related] [Next] [New Search]